Cargando…

Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study

BACKGROUND: Elderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority assignment policy. AIM: The aim of this study was to provide useful insight into the antibody generation taking place post-immunization...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kontopoulou, Konstantina, Nakas, Christos Theodore, Ainatzoglou, Alexandra, Ifantidou, Athina, Ntotsi, Paschalina, Katsioulis, Christos, Papazisis, Georgios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502633/ https://www.ncbi.nlm.nih.gov/pubmed/34633648 http://dx.doi.org/10.1007/s40520-021-01997-7

Ejemplares similares

Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece
por: Kontopoulou, Konstantina, et al.
Publicado: (2022)

Serum Proteome Signatures of Anti-SARS-CoV-2 Vaccinated Healthcare Workers in Greece Associated with Their Prior Infection Status †
por: Stamoula, Eleni, et al.
Publicado: (2022)

Study Protocol: The Feeding Exercise Randomized Trial among Overweight and Obese Adolescents in Greece
por: Patsopoulou, Anna, et al.
Publicado: (2022)

Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Knowledge, Attitudes, and Practices about the Prevention of Mosquito Bites and Zika Virus Disease in Pregnant Women in Greece
por: Mouchtouri, Varvara A., et al.
Publicado: (2017)

Knowledge and awareness about and use of iodised salt among students in Germany and Greece
por: Heimberg, Katharina, et al.
Publicado: (2022)

Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
por: Bauernfeind, Stilla, et al.
Publicado: (2021)

Pertussis Prevalence in Adult Population in Greece: A Seroprevalence Nationwide Study
por: Papagiannis, Dimitrios, et al.
Publicado: (2022)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
por: Priddy, Frances H., et al.
Publicado: (2022)

Prevalence of tobacco use, exposure to secondhand smoke and knowledge on smoking cessation among students of health professions in Central Greece: a cross-sectional study
por: Samara, Athina A, et al.
Publicado: (2020)

Prevalence and Risk Factors of Overweight and Obesity among Adolescents and Their Parents in Central Greece (FETA Project)
por: Patsopoulou, Anna, et al.
Publicado: (2015)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021)

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
por: Valentini, Diletta, et al.
Publicado: (2022)

Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
por: Leung, Daniel, et al.
Publicado: (2023)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
por: Naruse, Hiroyuki, et al.
Publicado: (2021)

Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
por: Karampitsakos, Theodoros, et al.
Publicado: (2022)

Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis
por: Michos, Athanasios, et al.
Publicado: (2022)

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong Kong
por: Mok, Chris Ka Pun, et al.
Publicado: (2021)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

Regional differences in mortality in Greece (1984–2004): The case of Thrace
por: Papastergiou, Panagiotis, et al.
Publicado: (2008)

Legionella Colonization of Hotel Water Systems in Touristic Places of Greece: Association with System Characteristics and Physicochemical Parameters
por: Kyritsi, Maria A., et al.
Publicado: (2018)

Age, Sex and BMI Relations with Anti-SARS-CoV-2-Spike IgG Antibodies after BNT162b2 COVID-19 Vaccine in Health Care Workers in Northern Greece
por: Papaioannidou, Paraskevi, et al.
Publicado: (2023)

A Case-Control Study on the Risk Factors for Meningococcal Disease among Children in Greece
por: Hadjichristodoulou, Christos, et al.
Publicado: (2016)

Validation of the Evidence-Based Practice Competence Questionnaire for Nursing Students: A Cross-Sectional Study in Greece
por: Patelarou, Athina, et al.
Publicado: (2021)

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
por: Tober-Lau, Pinkus, et al.
Publicado: (2021)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient
por: Agrati, Chiara, et al.
Publicado: (2021)

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer
por: Funakoshi, Yohei, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
por: Vargas-Herrera, Natalia, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon
por: Moghnieh, Rima, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
por: Levy, Itzchak, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rvc3pogmvo5dr24ttbhs1on85g